PURE Bioscience CEO Reviews Positive Business Outlook at Wall Street Analyst Forum Presentation
Reiterates Expectation for Profitability in Calendar 2008
SAN DIEGO, Calif., November 29, 2007 -- PURE Bioscience (OTCBB: PURE), creators of patented silver dihydrogen citrate (SDC), the active ingredient in a revolutionary new hard surface disinfectant which kills Staph/MRSA as well as other human pathogens, provided the following overview of the comments about the Company’s positive business outlook made yesterday by the Company’s CEO,
Krall reiterated his belief, as stated last month at a previous presentation, that PURE expects to close in the next 30 – 90 days on four new significant licensing/distribution agreements currently in process with new partner companies. He also reiterated that, for a number of reasons, calendar 2008 would be a ‘break out year’ for the Company, and that he expects PURE to be cash flow positive no later than the second calendar quarter. Krall said that he ‘vehemently disagrees’ with a published analyst report which estimates profitability in 2011. The Company completed an $8 million equity financing last month and, based upon the present business plan, does not anticipate the need to raise additional capital in the foreseeable future.
Krall also mentioned that PURE has shipped bulk Cruise ControlTM product to one of its distributors for implementation in field testing by two cruise lines. Cruise Control is a new SDC-based dilutable concentrate product to be marketed to the cruise ship industry. As verified in independent, third party laboratory tests, Cruise Control is the first hard surface disinfectant to offer 24-hour residual protection against Norovirus. The present market for hard surface disinfectant used by the cruise lines is estimated to be in excess of $300 million. Cruise Control offers several unique competitive advantages and is cost competitive.
Previously announced distributors in
The progress of the continued development of SDC as an active pharmaceutical ingredient and the status of the
Krall stated that the Company presently satisfies the listing requirements for Nasdaq with the exception of the need to name one additional independent member to its Board of Directors. That selection process is currently underway and the Company will apply for the national stock exchange listing as soon as that new Board member is named.
A replay for the presentation is available at www.wsw.com/webcast/wsaf5/pure.ob.
Revolutionary Disinfecting Agent
SDC is an electrolytically generated source of stabilized ionic silver. A patented new molecular entity, SDC is distinguished from competitors because of its superior efficacy and reduced toxicity. PURE produces and markets ready-to-use EPA-registered disinfectant products, as well as varying strengths of SDC concentrate as an active ingredient, additive or preservative for inclusion in third party products, including householder and personal care products. PURE also pursues development programs for SDC as an active pharmaceutical ingredient in a variety of pharmaceutical products.
As previously reported, PURE’s EPA registered antimicrobial has eliminated Staph/MRSA infections in the Tulsa County Jail since that facility began using the hard surface disinfectant in August 2006. The jail, with 1,700 cells and more than 1,500 inmates, had historically faced challenges with Staph. Prior to its use of the SDC disinfectant, the facility experienced, on average, 12 cases of Staph infection every month. The first new disinfectant active to be registered by the EPA in more than 30 years, SDC-based products are antiviral, antifungal and antibacterial, including a 30-second kill time and 24-hour residual protection against standard indicator bacteria and a 2-minute kill claim on MRSA (Methicillin-resistant Staphylococcus aureus), CA-MRSA, PVL-MRSA and VRE (Vancomycin resistant Enterococcus faecium). Notable viral efficacy claims for PURE’s disinfectant include a three-minute kill against Human Corona virus (SARS surrogate) and Rotavirus and a ten-minute kill against Norovirus and Avian Influenza A (Bird Flu). Moreover, SDC-based disinfectants pose little if any health hazards because they are odorless, colorless, non-corrosive, non-flammable and are compatible with other disinfecting and cleaning chemicals. SDC-based disinfectants carry the EPA Category IV lowest-toxicity rating.
Tremendous Pharmaceutical Potential
Last month, PURE announced the Current Good Manufacturing Practice (cGMP) certification of PURE’s manufacturing facility and process for the production of its pharmaceutical-grade silver dihydrogen citrate (SDC) concentrate as an Active Pharmaceutical Ingredient (API). In addition, PURE has completed the Registration of Drug Establishment with the US Food and Drug Administration (FDA).
Clinical studies are underway related to an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) by San Diego-based Therapeutics, Inc. for a hand sanitizer based upon PURE's SDC antimicrobial. PURE also granted Therapeutics, Inc. a license to develop four additional SDC-based products for the treatment and prevention of dermatological and women's health related bacterial, viral and fungal mediated diseases and conditions. Therapeutics has assumed responsibility for funding and directing the testing and regulatory processes for these selected potential FDA-regulated SDC-based products and anticipates filing four additional product INDs. Additional pharmaceutical partnership development is underway or being sought for medical devices, systemic antibiotics/antivirals and dental and veterinary applications.
About PURE Bioscience
PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project,” "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.